Clinical Trial Update: A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors [Phase 1]

View source ↗

Summary

A Phase I trial evaluated the tolerability of 225Ac-DOTATATE in patients with refractory or relapsed multiple myeloma expressing somatostatin receptors, but the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• 225Ac-DOTATATE

Snippet

Sponsor: Jules Bordet Institute | Conditions: Multiple Myeloma, Refractory, Multiple Myeloma in Relapse | Phase 1 | Status: WITHDRAWN